A promising approach for the treatment of IGS-associated diseases is active immunization with IFNα-kinoid, a therapeutic vaccine consisting of inactivated recombinant human IFNα2b and a carrier protein, the keyhole limpet haemocyanin, which can induce a strong polyclonal antibody response against IFNα and thus reduce IGS in patients with SLE [259,260]. Here, IFNA1 is linked to systemic lupus erythematosus.